Disease activity-guided tapering of biologics in patients with inflammatory arthritis: a pragmatic, randomized, open-label, equivalence trial

類似資料

• Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial
  著者:: Uhrenholt, L, 等
  出版事項: (2024)
• Predicting successful biologics tapering in patients with inflammatory arthritis: Secondary analyses based on the BIOlogical Dose OPTimisation (BIODOPT) trial
  著者:: Uhrenholt, L, 等
  出版事項: (2023)
• Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis
  著者:: Uhrenholt, L, 等
  出版事項: (2021)
• Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)
  著者:: Ellen-Margrethe Hauge, 等
  出版事項: (2019-07-01)
• Agreement between patient-reported outcome measures collected via a smartphone application vs a touchscreen solution in an outpatient clinic among patients with inflammatory arthritis: a randomised, within-participant trial
  著者:: Uhrenholt, L, 等
  出版事項: (2020)